Skip to main content
OpenTrials
Completed

NCT Number: NCT03663634

Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin B

Vienna Consensus has identified 10% damage rate after ICSI as a competency value. Despite the highest quality embryologists doing ICSI, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. Cytochalasin B serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. Using Cytochalasin B during ICSI could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes,

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infertility Genital Diseases Urogenital Diseases

Age range

18 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

IbnSina IVF Center

Sohag, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All ICSI candidates patients

Exclusion criteria

  • No exclusion

Treatment and study plan

Cytochalasin B use in ICSI handling medium

Other

A medium with in-house supplementation of Cytochalasin B to decrease oocyte degeneration after ICSI and improve survival rate

Primary outcomes

  1. oocyte survival rate

    Time frame: 6 days of culture

    number of survived oocyte after intracytoplasmic sperm injection

Secondary outcomes

  1. fertilization rate

    Time frame: 6 days of culture

    number of fertilized oocytes per metaphase II injected

  2. blastocyst formation rate

    Time frame: 6 days of culture

    number of formed blastocyst per fertilized oocyte

  3. embryo utilization rate

    Time frame: 6 days of culture

    number of embryo transferred added to number of those cryopreserved per fertilized oocyte

  4. clinical pregnancy rate

    Time frame: three months

    number of women with a heartbeat at week 4 or more after embryo transfer

  5. ongoing pregnancy rate

    Time frame: four months

    number of women with continued pregnancy after twelve weeks of gestation

Sponsors and collaborators

Lead sponsor

Ibn Sina Hospital

Other Gov

Collaborators

  • Banoon IVF Center

Registry information

Official study title

Cytochalasin B Supplementation to ICSI Handling Medium

Acronym: ICSI-CB

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Sep 10, 2018
Registry last updated
Aug 7, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.